PDGFRB and glioblastoma: Interestingly, the anti-GBM properties of Gint4.T/CL4 combined aptamers were compared with three commercial anticancer drugs—gefitinib and cetuximab (both drugs against EGFR) and imatinib (against PDGFR) [49].